Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition

Journal of Cellular Physiology

Volumn 196, Issue 1, 2003, Pages 171-179

  Henriksen, Erik J ^a   Jacob, Stephan ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Albert Schweizer Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ B2 RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 4; GROWTH FACTOR; IMIDAPRIL; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RAMIPRIL; RECEPTOR SUBUNIT; TEMOCAPRIL; TRANDOLAPRIL; TRANDOLAPRILAT; UNINDEXED DRUG; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ARTICLE; BIOSYNTHESIS; BLOOD PRESSURE REGULATION; CELL SURFACE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE TRANSPORT; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UPREGULATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MUSCLE, SKELETAL; PEPTIDYL-DIPEPTIDASE A;

RODENTIA;

EID: 0037607814     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.10294     Document Type: Article

References (101)

1. Alberti KGMM, Zimmet PZ, for the WHO Consultation. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 15:539-553.
2. Arbin V, Claperon N, Fournie-Zaluski M-C, Roques BP, Peyroux J. 2001. Acute effect of the dual angiotensin-converting enzyme and neutral peptidase 24-11 inhibitor mixanpril on insulin sensitivity in the obese Zucker rat. Br J Pharmacol 133:495-502.
3. Azevedo JL, Carey JO, Pories WJ, Morris PG, Dohm GL. 1995. Hypoxia stimulates glucose transport in insulin-resistant human skeletal muscle. Diabetes 44:695-698.
4. Balon TW, Nadler JL. 1994. Nitric oxide is present from incubated skeletal muscle. J Appl Physiol 77:2519-2521.
5. Balon TW, Nadler JL. 1997. Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl Physiol 82:359-363.
6. Baron AD, Brechtel G, Wallace P, Edelman SV. 1988. Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol Endocrinol Metab 255:E769-E774.
7. Bhoola KD, Ergueros CD, Worthy K. 1992. Bioregulation of kinins: Kallekreins, kininogens, and kinases. Pharmacol Rev 44:1-80.
8. Björnholm M, Kawano Y, Lehtihet M, Zierath JR. 1997. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol-3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 46:524-527.
9. Cartee GD, Douen AG, Ramlal T, Klip A, Holloszy JO. 1991. Stimulation of glucose transport in skeletal muscle by hypoxia. J Appl Physiol 70:1593-1600.
10. Carvalho CRO, Thirone ACP, Gontijo JAR, Velloso LA, Saad MJA. 1997. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 46:1950-1957.
11. Chaudry IH, Gould MK. 1970. Effect of externally added ATP on glucose uptake by isolated rat soleus muscle. Biochim Biophys Acta 196:327-335.
12. Constable SH, Favier RJ, Uhl J, Holloszy JO. 1986. Bradykinin does not mediate activation of glucose transport by muscle contraction. J Appl Physiol 61:881-884.
13. Dal Ponte DB, Fogt DL, Jacob S, Henriksen EJ. 1998. Interactions of captopril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism 47:982-987.
14. DeFronzo RA, Ferrannini E. 1991. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194.
15. DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J. 1983. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes 32:32-45.
16. Dietze GJ, Wicklmayr M, Rett K, Jacob S, Henriksen EJ. 1996. Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes 45:S110-S114.
17. Dragovic T, Minshall R, Jackman HL, Wang L-X, Erdös EG. 1996. Kininase II-type enzymes. Their putative role in muscle energy metabolism. Diabetes 45(Suppl 1):S34-S37.
18. Erdös E. 1975. Angiotensin I converting enzyme. Circ Res 36:247-255.
19. Etgen GJ, Wilson CM, Jensen J, Cushman SW, Ivy JL. 1996. Glucose transport and cell surface GLUT-4 protein in skeletal muscle of the obese Zucker rat. Am J Physiol Endocrinol Metab 271:E294-E301.
20. Etgen GJ, Fryburg DA, Gibbs EM. 1997. Nitric oxide stimulates skeletal muscle glucose transport through a calcium/contraction- and phosphatidylinositol-3-kinase-independent pathway. Diabetes 46:1915-1919.
21. 2 receptors on skeletal muscle cells. Diabetes 45:S24-S28.
22. Foianini KR, Steen MS, Kinnick TR, Schmit MB, Youngblood EB, Henriksen EJ. 2000. Effects of exercise training and trandolapril treatment on insulin action in rat skeletal muscle. J Appl Physiol 89:687-694.
23. Folli F, Saad MJ, Velloso LA, Hansen H, Feener EP, Kahn CR. 1999. Crosstalk between insulin and-angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 107:133-139.
24. Friedman JE, Sherman WM, Reed MJ, Elton CW, Dohm GL. 1990. Exercise training increases glucose transporter protein GLUT-4 in skeletal muscle of obese Zucker (fa/fa) rats. FEBS Lett 268:13-16.
25. Gao J, Ren J, Gulve EA, Holloszy JO. 1994. Additive effect of contractions and insulin on GLUT-4 translocation into the sarcolemma. J Appl Physiol 77:1587-1601.
26. Ginsberg HN. 2000. Insulin resistance and cardiovascular disease. J Clin Invest 106:453-458.
27. Goodyear LJ, Kahn BB. 1998. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 49:235-261.
28. Goodyear LJ, Hirshman MF, Horton ES. 1991. Exercise-induced translocation of skeletal muscle glucose transporters. Am J Physiol Endocrinol Metab 261:E795-E799.
29. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL. 1995. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95:2195-2204.
30. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. 1998. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234.
31. Halbert JA, Silagy CA, Finucane P, Withers RT, Hamdorf PA, Andrews GR. 1997. The effectiveness of exercise training in lowering blood pressure: A meta-analysis of randomised controlled trials of 4 weeks or longer. J Hum Hypertension 11:641-649.
32. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. 1999. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611-616.
33. HOPE Study investigators. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramapril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153.
34. Heinemann L, Heise T, Ampudia J, Sawicki P, Sindelka G, Brunner G, Starke AA. 1995. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: No influence on insulin sensitivity. Eur J Clin Invest 25:595-600.
35. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT. 1999. Insulin sensitivity in patients with essential hypertension: No influence of the ACE inhibitor enalapril. Horm Metabol Res 31:418-423.
36. Henriksen EJ, Jacob S. 1995. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 44:267-272.
37. Henriksen EJ, Bourey RE, Rodnick KJ, Koranyi L, Permutt MA, Holloszy JO. 1990. Glucose transporter protein content and glucose transport capacity in rat skeletal muscles. Am J Physiol Endocrinol Metab 259:E593-E598.
38. Henriksen EJ, Jacob S, Fogt DL, Dietze GJ. 1998. Effect of chronic bradykinin administration on insulin action in an animal model of insulin resistance. Am J Physiol Regul Integr Comp Physiol 275: R40-R45.
39. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ. 1999. ACE inhibition and glucose transport in insulin-resistant muscle: Roles of bradykinin and nitric oxide. Am J Physiol Regul Integr Comp Physiol 277:R332-R336.
40. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. 2001. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38:884-890.
41. Higaki Y, Hirshman MF, Fujii N, Goodyear LJ. 2001. Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. Diabetes 50:241-247.
42. Higashiura K, Ura N, Miyazaki Y, Shimamoto K. 1999. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. J Human Hypertens 13(Suppl 1):S71-S74.
43. Higashiura K, Ura N, Takada T, Li Y, Torii T, Togashi N, Takada M, Takizawa H, Shimamoto K. 2000. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 13:290-297.
44. Holloszy JO, Hansen PA. 1996. Regulation of glucose transport into skeletal muscle. Rev Physiol Biochem Pharmacol 128:99-193.
45. Holloszy JO, Narahara HT. 1965. Studies of tissue permeability. X. Changes in permeability to 3-methylglucose associated with contraction of frog muscle. J Biol Chem 240:3493-3500.
46. Jacob S, Warth B, Thies R, Gross A, Augustin HJ, Dietze GJ. 1993. Acute effects of various doses of captopril on glucose metabolism in humans. Third International Symposium on ACE Inhibition, Amsterdam, The Netherlands.
47. Jacob S, Streeper RS, Fogt DL, Hokama JY, Tritschler HJ, Dietze GJ, Henriksen EJ. 1996a. The antioxidant alpha-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle. Diabetes 45:1024-1029.
48. Jacob S, Henriksen EJ, Fogt DL, Dietze GJ. 1996b. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism 45:535-541.
49. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G. 1987. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 17:448-454.
50. Kapur S, Bedard S, Marcotte B, Cote CH, Marette A. 1997. Expression of nitric oxide synthase in skeletal muscle. A novel role for nitric oxide as a modulator of insulin action. Diabetes 46:1691-1700.
51. King PA, Betts JJ, Horton ED, Horton ES. 1993. Exercise, unlike insulin, promotes glucose transporter translocation in obese Zucker rat muscle. Am J Physiol Regul Integr Comp Physiol 265:R447-R452.
52. Kinnick TR, Youngblood EB, O'Keefe MP, Saengsirisuwan V, Teachey MK, Henriksen EJ. 2002. Modulation of insulin resistance and hypertension by voluntary exercise training in the TG(mREN2)27 rat. J Appl Physiol 93:805-813.
53. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J. 1990. Effect of captopril on glucose concentration. Possible role of augmented postprandrial forearm blood flow. Diabetes Care 13:1109-1111.
54. Kokkinos PF, Papademetriou V. 2000. Exercise and hypertension. Coron Artery Dis 11:99-102.
55. Krook A, Roth RA, Jiang XJ, Zierath JR, Wallberg-Henriksson H. 1998. Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes 47:1281-1286.
56. Krook A, Björnholm M, Galuska D, Jiang XJ, Fahlman R, Myers MG, Jr., Wallberg-Henriksson H, Zierath JR. 2000. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49:284-292.
57. Lee MA, Bohm M, Paul M, Bader M, Ganten U, Ganten D. 1996. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol Endocrinol Metab 270:E919-E929.
58. Leighton B, Sanderson AL, Young ME, Radda GK, Boehm EA, Clark JF. 1996. Effects of treatment of spontaneously hypertensive rats with the angiotensin-converting enzyme inhibitor trandolapril and the calcium antagonist verapamil on the sensitivity of glucose metabolism to insulin in rat soleus muscle in vitro. Diabetes 45:S120-S124.
59. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. 1999. A double blind comparison of the effects of amlopidine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 12:298-303.
60. Mann WR, Villauer EB, Barilla D, Battle B, Dunning BE, Balkan B. 1995. Effects of bradykinin on glucose metabolism in isolated rat soleus muscle and on blood glucose levels in Ob/Ob mice (Abstract). Diabetes 44:133A.
61. Mitchell D, Tyml K. 1996. Nitric oxide release in rat skeletal muscle capillary. Am J Physiol Heart Circ Physiol 270:H1696-H1703.
62. 2 receptor in dog skeletal muscle and rat L6 myoblasts. Eur J Endocrinol 138:344-352.
63. Morel Y, Gadient A, Keller U, Vadas L, Golay A. 1995. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol 26:306-311.
64. Nawano M, Anai M, Funaki M, Kobayashi H, Kanda A, Fukushima Y, Inukai K, Ogihara T, Sakoda HH, Onishi Y, Kikuchi M, Yazaki Y, Oka Y, Asano T. 1999. Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism 48:1248-1255.
65. Nesher R, Karl IE, Kipnis DM. 1985. Dissociation of effects of insulin and contraction on glucose transport in rat epitrochlearis muscle. Am J Physiol Cell Physiol 249:C226-C232.
66. New JP, Bilous RW, Walker M. 2000. Insulin sensitivity in hypertensive type 2 diabetic patients after 1 and 19 days' treatment with trandolapril. Diab Med 17:134-140.
67. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M. 1992. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Human Hypertens 6:175-179.
68. Pedersen O, Bak JF, Andersen PH, Lund S, Moller DE, Flier JS, Kahn BB. 1990. Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes 39:865-870.
69. Petrella RJ. 1998. How effective is exercise training for the treatment of hypertension? Clin J Sports Med 8:224-231.
70. Petrie JR, Morris AD, Ueda S, Small M, Donnelly R, Connell JM, Elliott HL. 2000. Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: A double-blind, placebo-controlled crossover trial. J Clin Endocrinol Metab 85:1882-1889.
71. Piedrola G, Novo E, Serrano-Gotarredona J, de Teresa ML, Garcia-Robles R. 1999. Evolution of insulin resistance in coronary artery disease patients on four different pharmacological therapies. Postgrad Med J 75:27-31.
72. Pollare T. 1990. Insulin sensitivity and blood lipids during antihypertensive treatment with special reference to ACE inhibition. J Diab Complic 4:75-78.
73. Pollare T, Lithell H, Berne C. 1989. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321:868-873.
74. Reaven GM. 1993. Role of insulin resistance in human disease (Syndrome X): An expanded definition. Annu Rev Med 44:121-131.
75. Reaven GM. 1995. Are insulin resistance and/or compensatory hyperinsulinemia involved in the etiology and clinical course of patients with hypertension? Int J Obesity 19:S2-S5.
76. Reaven GM, Clinkingbeard C, Jeppesen J, Maheux P, Pei D, Foote J, Hollenbeck CB, Chen YD. 1995. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 8:461-466.
77. Rett K, Wicklmayr M, Dietze GJ, Häring HU. 1996. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 45:S66-S69.
78. Rett K, Maerker E, Renn W, van Gilst W, Häring HU. 1997. Perfusion-independent effect of bradykinin and fosinoprilate on glucose transport in Langendorff rat hearts. Am J Cardiol 80:143A-147A.
79. Richey JM, Ader M, Moore D, Bergman RN. 1999. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol Endocrinol Metab 277:E920-E926.
80. Roberts CK, Barnard RJ, Scheck SH, Balon TW. 1997. Exercise-stimulated glucose transport in skeletal muscle is nitric oxide dependent. Am J Physiol Endocrinol Metab 273:E220-E225.
81. Roy D, Perreault M, Marette A. 1998. Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO-dependent. Am J Physiol Endocrinol Metab 274:E692-E699.
82. Ryder JW, Yang J, Galuska D, Rincon J, Björnholm M, Krook A, Lund S, Pedersen O, Wallberg-Henriksson H, Zierath JR, Holman GD. 2000. Use of a novel impermeable biotinylated photolabeling reagent to assess insulin- and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients. Diabetes 49:647-654.
83. Ryder JW, Chibalin AV, Zierath JR. 2001. Intracellular mechanisms underlying increases in glucose uptake in response to insulin or exercise in skeletal muscle. Acta Physiol Scand 171:249-257.
84. Sasaki K, Kushiro T, Nakagawa S, Kanmatsuse K. 1999. Effects of angiotensin II receptor antagonism on insulin sensitivity and sympathetic activity in spontaneously hypertensive rats. Jap J Nephrol 41:692-696.
85. Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T. 1995. The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am J Hypertens 8:276-281.
86. Shepherd PR, Kahn BB. 1999. Glucose transporters and insulin action. Implications for insulin resistance and diabetes mellitus. N Eng J Med 341:248-257.
87. Shieh SM, Sheu WHH, Shen DDC, Fuh MM, Jeng CY, Jeng JR, Chen YD, Reaven GM. 1992. Improvements in metabolic risk factors for coronary heart disease associated with cilazapril treatment. Am J Hypertens 5:506-510.
88. Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M. 2002. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 40:329-334.
89. Steen MS, Foianini KR, Youngblood EB, Kinnick TR, Jacob S, Henriksen EJ. 1999. Interactions of exercise training and ACE inhibition on insulin action in obese Zucker rats. J Appl Physiol 86:2044-2051.
90. Suzuki M, Ikebuchi M, Yokota C, Shinozaki K, Harano Y. 1995. Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. Clin Exp Hypertens 17:1257-1268.
91. Taguchi T, Kishikawa H, Motoshima H, Sakai K, Nishiyama T, Yoshizato K, Shirakami A, Toyonaga T, Shirontani T, Araki E, Shirichi M. 2000. Involvement of bradykinin in acute exercise-induced increase of glucose uptake and GLUT-4 translocation in skeletal muscle: Studies with normal and diabetic humans and rats. Metabolism 49:920-930.
92. Torlone E, Britta M, Rambotti AM, Perriello G, Santeusanio F, Brunetti P, Bolli GB. 1993. Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes. Diabetes Care 16:1347-1355.
93. Uehara M, Kishikawa H, Isami S, Kisanuki K, Ohkubo Y, Miyamura N, Miyata T, Yano T, Shichiri M. 1994. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: Bradykinin may improve insulin resistance in dogs and humans. Diabetologia 37:300-307.
94. UKPDS Study Group. 1998. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J 317:713-720.
95. Vuirinen-Markkola H, Yki-Järvinen H. 1995. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 44:85-89.
96. Wicklmayr M, Dietze GJ. 1979. Improvement of insulin action by bradykinin in the alloxan-diabetic rat. FEBS Lett 106:125-128.
97. Winder WW. 2001. Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J Appl Physiol 91:1017-1028.
98. Young ME, Leighton B. 1998. Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle. Biochem J 329:73-79.
99. Young ME, Radda GK, Leighton B. 1997. Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem J 322:223-228.
100. Zierath JR, He L, Guma A, Odegaard-Wahlstrom E, Klip A, Wallberg-Henriksson H. 1996. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 39:1180-1189.
101. Zierath JR, Krook A, Wallberg-Henriksson H. 2000. Insulin action and insulin resistance in human skeletal muscle. Diabetologia 43:821-835.